AstraZeneca and Daiichi Sankyo said Monday they received FDA approval for their [fam-] trastuzumab deruxtecan-nxki, which will be marketed as Enhertu. [Fam-] trastuzumab deruxtecan is an antibody–drug conjugate (ADC) designed to delivery cytotoxic chemotherapy to cancer cells via a human epidermal receptor 2 (HER2) antibody attached to a novel topoisomerase I inhibitor payload and a tetrapeptide-based linker.
AstraZeneca and Daiichi Sankyo said Monday they received FDA approval for their [fam-] trastuzumab deruxtecan-nxki, which will be marketed as Enhertu. [Fam-] trastuzumab deruxtecan is an antibody—drug conjugate (ADC) designed to delivery cytotoxic chemotherapy to cancer cells via a human epidermal receptor 2 (HER2) antibody attached to a novel topoisomerase I inhibitor payload and a tetrapeptide-based linker.
The approval is for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2-based regimens.
The company recently presented results from its pivotal phase 2 study, DESTINY-Breast01, at the at the San Antonio Breast Cancer Symposium in San Antonio, Texas and also published in The New England Journal of Medicine.
The companies said in a statement the clearance came under Accelerated Approval based on tumor response rate and duration of response. “Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial,” the companies said.
In DESTINY, 184 female patients with HER2-positive metastatic breast cancer received 5.4 mg/kg of Enhertu as a monotherapy; all patients previously were treated with prior trastuzumab, ado-trastuzumab emtansine, and 66% had prior pertuzumab.
The phase 2 trial results showed a confirmed objective response rate of 60.3% (n = 111; 95% CI, 52.9-67.4), including a 4.3% complete response rate (n = 8) and a 56.0% partial response rate (n = 103). A median duration of response of 14.8 months (95% CI, 13.8-16.9) was demonstrated as of August 1, 2019.
In addition, patients had a median progression-free survival of 16.4 months (95% CI, 12.7-not estimable), based upon a median duration of follow-up of 11.1 months.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.